EA200601545A1 - АНТИ-Aβ АНТИТЕЛА - Google Patents

АНТИ-Aβ АНТИТЕЛА

Info

Publication number
EA200601545A1
EA200601545A1 EA200601545A EA200601545A EA200601545A1 EA 200601545 A1 EA200601545 A1 EA 200601545A1 EA 200601545 A EA200601545 A EA 200601545A EA 200601545 A EA200601545 A EA 200601545A EA 200601545 A1 EA200601545 A1 EA 200601545A1
Authority
EA
Eurasian Patent Office
Prior art keywords
abeta
free
low levels
abeta peptide
acceptably low
Prior art date
Application number
EA200601545A
Other languages
English (en)
Other versions
EA009872B1 (ru
Inventor
Рональд Брэдли Дематтос
Ума Кучибхотла
Си-Чиун Ян
Дон Б. Макклур
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200601545A1 publication Critical patent/EA200601545A1/ru
Publication of EA009872B1 publication Critical patent/EA009872B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Настоящее изобретение представляет композицию, пригодную для введения человеку, включающую анти-Аβ антитело без Аβ-пептида или имеющую допустимо низкие уровни содержания его, свободную от нечеловеческого Аβ-пептида или имеющую допустимо низкие уровни содержания его, или имеющую недетектируемое содержание Аβ-пептида.
EA200601545A 2004-02-23 2005-02-17 АНТИ-Aβ АНТИТЕЛА EA009872B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
PCT/US2005/005198 WO2005082939A2 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (2)

Publication Number Publication Date
EA200601545A1 true EA200601545A1 (ru) 2007-02-27
EA009872B1 EA009872B1 (ru) 2008-04-28

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601545A EA009872B1 (ru) 2004-02-23 2005-02-17 АНТИ-Aβ АНТИТЕЛА

Country Status (20)

Country Link
US (1) US20070190046A1 (ru)
EP (1) EP1720909B1 (ru)
JP (1) JP4851348B2 (ru)
KR (2) KR100889430B1 (ru)
CN (1) CN1922209B (ru)
AT (1) ATE534667T1 (ru)
AU (1) AU2005217596B2 (ru)
BR (1) BRPI0507856A (ru)
CA (1) CA2556436C (ru)
CY (1) CY1112162T1 (ru)
DK (1) DK1720909T3 (ru)
EA (1) EA009872B1 (ru)
ES (1) ES2375627T3 (ru)
IL (1) IL177611A (ru)
NO (1) NO20064239L (ru)
PL (1) PL1720909T3 (ru)
PT (1) PT1720909E (ru)
SI (1) SI1720909T1 (ru)
UA (1) UA93181C2 (ru)
WO (1) WO2005082939A2 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
BRPI0619748B8 (pt) 2005-12-12 2021-05-25 Ac Immune Sa anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste
CA2657681C (en) 2006-07-14 2019-03-19 Ac Immune S.A. Humanized antibodies against beta amyloid protein
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PL2104682T3 (pl) 2007-01-11 2017-03-31 Michael Bacher Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
BRPI0921837A2 (pt) 2008-11-25 2016-01-12 Biogen Idec Inc anticorpos isolados ou fragmentos de antígeno de ligação dos mesmos que podem se ligar especificamente a um polipeptídio dr6, métodos in vitro de promover a sobrevivência de uma célula do sistema nervoso, usos de um antagonista dr6 e métodos in vitro de inibir a ligação de dr6 com p75
MX2011006422A (es) 2008-12-19 2011-09-15 Panima Pharmaceuticals Ag Autoanticuerpos humanos anti-alfa-sinucleina.
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
EA030777B9 (ru) 2011-06-23 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Анти-альфа-синуклеинсвязывающие молекулы
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP3458076A4 (en) 2016-05-16 2020-01-22 The General Hospital Corporation HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL
WO2018031334A1 (en) * 2016-08-11 2018-02-15 Eli Lilly And Company Aminothiazines and their use as bace1 inhibitors
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
WO2022150735A1 (en) 2021-01-11 2022-07-14 Eli Lilly And Company Anti-n3pglu amyloid beta antibodies and uses thereof
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129820A0 (en) 1996-12-23 2000-02-29 Elan Pharm Inc Cycloalkyl lactam lactone and related compounds as beta-amyloid peptide release inhibitors
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
CN101670105B (zh) * 2000-02-24 2014-08-06 华盛顿大学 螯合淀粉样蛋白β肽的人源化抗体
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7318923B2 (en) * 2001-04-30 2008-01-15 Eli Lilly And Company Humanized anti-βantibodies

Also Published As

Publication number Publication date
CA2556436C (en) 2014-04-01
PT1720909E (pt) 2011-12-23
AU2005217596B2 (en) 2012-01-19
CY1112162T1 (el) 2015-12-09
CN1922209A (zh) 2007-02-28
NO20064239L (no) 2006-11-20
KR20060126785A (ko) 2006-12-08
JP2008500279A (ja) 2008-01-10
CN1922209B (zh) 2012-09-05
DK1720909T3 (da) 2012-01-30
US20070190046A1 (en) 2007-08-16
WO2005082939A2 (en) 2005-09-09
EA009872B1 (ru) 2008-04-28
KR100889430B1 (ko) 2009-03-23
SI1720909T1 (sl) 2012-01-31
IL177611A (en) 2013-05-30
WO2005082939A3 (en) 2005-10-27
CA2556436A1 (en) 2005-09-09
EP1720909B1 (en) 2011-11-23
BRPI0507856A (pt) 2007-07-10
AU2005217596A1 (en) 2005-09-09
UA93181C2 (ru) 2011-01-25
PL1720909T3 (pl) 2012-04-30
ATE534667T1 (de) 2011-12-15
ES2375627T3 (es) 2012-03-02
KR20090005410A (ko) 2009-01-13
IL177611A0 (en) 2006-12-10
EP1720909A2 (en) 2006-11-15
JP4851348B2 (ja) 2012-01-11

Similar Documents

Publication Publication Date Title
EA200601545A1 (ru) АНТИ-Aβ АНТИТЕЛА
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
EA200702402A1 (ru) Агенты, связывающие склеростин
CY1116632T1 (el) Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200800812A1 (ru) Композиции антитела против cd3
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
CO5720212A1 (es) Composicion de anticuerpo her2
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
CU24058B1 (es) Antagonistas de pcsk9
EA201291226A1 (ru) Композиции с высокой концентрацией антител
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
EA201100527A1 (ru) Биологические продукты
MX348432B (es) Epitopes.
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
EA201991701A1 (ru) Состав на основе моноклонального антитела к rsv
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
EA200800601A1 (ru) Связывающие fas антитела
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
DK1987057T3 (da) Peptidaptamer til neutralisering af bindingen af platelet-antigen-specifikke antistoffer og diagnostiske og terapeutiske applikationer indeholdende den.
EA200900991A1 (ru) Новые антитела против igf-1r

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU